Loading
An injection that helps the marrow finish making red cells, reducing or removing the need for transfusions in lower-risk MDS and beta-thalassaemia.
MEDALIST (2020) established transfusion independence in ring-sideroblast MDS after ESA failure; COMMANDS (2023) showed superiority to epoetin alfa in ESA-naive lower-risk MDS, making it a first-line option. Also approved in beta-thalassaemia (BELIEVE) and studied in myelofibrosis anaemia (INDEPENDENCE).
Binds TGF-β superfamily ligands (GDF11, activin B) to relieve SMAD2/3 suppression of late-stage erythropoiesis.
1.Luspatercept binds its target.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Subcutaneous injection every three weeks by a clinician; HCPCS J0896.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments. Transfusion burden and erythropoiesis-stimulating agent history documented for MDS.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA844. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2019 | Beta-thalassaemia transfusion-dependent anaemia |
| US | 2020 | Very low- to intermediate-risk MDS with ring sideroblasts after ESA failure |
| US | 2023 | First-line anaemia in ESA-naive lower-risk MDS |
| EU | 2020 | MDS-RS and beta-thalassaemia |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
IMerge validated telomerase as a drug target in cancer, decades after its discovery, and gave a second-line option for MDS patients whose anaemia no longer responds to erythropoietin or luspatercept. The hint of clonal reduction is what makes the drug interesting beyond transfusion counts. Cytopenias require close monitoring in the first cycles.
COMMANDS moved luspatercept from second line (after ESA failure, MEDALIST trial) to first line, offering transfusion-dependent lower-risk MDS patients a better chance of transfusion freedom from the start. It changed guidelines and labels in 2023. Erythropoietin remains a reasonable and cheaper option for patients without ring sideroblasts or with low transfusion burden.
Query for this drug: (TITLE:"Luspatercept" OR ABSTRACT:"Luspatercept" OR TITLE:"Reblozyl" OR ABSTRACT:"Reblozyl") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Luspatercept, not a curated reading list.
Shares IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed, COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions, Anaemia, SF3B1 mutation.
Shares COMMANDS, Lower-risk myelodysplastic syndromes, Transfusion support and anaemia management, Primary myelofibrosis.
Shares MEDALIST, IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed, Myelodysplastic syndromes / neoplasms (MDS).
Shares Lower-risk myelodysplastic syndromes, Primary myelofibrosis, Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares COMMANDS, COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions, Myelodysplastic syndromes / neoplasms (MDS).
Shares IPSS-R and IPSS-M (myelodysplastic syndrome risk scores), Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Myelodysplastic syndromes / neoplasms (MDS).
Shares IPSS-R and IPSS-M (myelodysplastic syndrome risk scores), Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Myelodysplastic syndromes / neoplasms (MDS).
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).